Introduction
Multiple endocrine neoplasia type 1 (MEN1; OMIM 131100) is an autosomal-dominant hereditary endocrine tumor syndrome. It is characterized by the combined development of anterior pituitary adenomas, adenomas or hyperplasia of the parathyroid glands, and gastroenteropancreatic neuroendocrine tumors (GEPNETs) in a single patient. Germline mutations in the menin gene (MEN1) account for the development of MEN1, and most of the MEN1 mutations are inactivating, which is consistent with the tumor-suppressing role of menin. More than 1000 different germline MEN1 mutations have been reported throughout the entire length of the coding and noncoding regions without significant clustering. Of all mutations, approximately 23% are nonsense mutations, 41% are frameshift deletions or insertions, 6% are in-frame deletions or insertions, 9% are splice-site mutations, and 20% are missense mutations (1) .
We describe herein a Japanese adolescent with MEN1 carrying a newly identified heterozygous missense mutation (p.Gly42Val) in MEN1.
Case Report
A 16-yr-old female initially presented at the age of 9 yr with a hypoglycemic (32 mg/dl) seizure associated with inappropriately elevated insulin concentrations (serum insulin, 13.4 µU/ ml; immunoreactive insulin level/blood sugar = 0.42; normal range, < 0.3). Abdominal enhanced computed tomography (CT) revealed a 2-cm solid mass localized in the pancreatic head (Fig. 1a) . A calcium arterial stimulation and venous sampling (ASVS) test was performed for the preoperative evaluation of this tumor. The insulin level in the hepatic venous blood increased from 18.2 to 141.6 µU/ml (7.78-fold) and 28.9 to 280.9 µU/ ml (9.72-fold) following the injection of calcium gluconate into the superior and the inferior pancreaticoduodenal arteries, respectively. A positive ASVS test result (a greater than 2-fold increase in the insulin level after stimulation) confirmed the presence of insulinoma. The patient underwent the surgical removal of the tumor, and a diagnosis of identified by magnetic resonance imaging (MRI) screening. At 16 yr of age, she was found to have persistent asymptomatic hypercalcemia (10.5 mg/dl; normal range, 8.5 to 10.3 mg/ dl) associated with an inappropriately high serum PTH level (95 pg/ml; normal range, 10 to 65 pg/ml). Ultrasonography of the thyroid demonstrated hypoechoic homogeneous nodules that were 9.8 × 3.8 mm and 10.5 × 3.3 mm in size and located posterior to the lower pole of the left lobe and the right lobe, respectively, of the thyroid (Fig. 1b) . The patient underwent surgical resection of the nodules, which were diagnosed as parathyroid adenomas by subsequent histopathology. Additional brain MRI scans revealed an 8.0 × 5.8 mm pituitary tumor (Fig. 1c) that was presumed to be a nonfunctioning pituitary adenoma because her pituitary hormone profiles were normal. Based on these clinical and biochemical findings, she was diagnosed as having MEN1. Her family members were healthy (Fig. 1d) . This patient has been enrolled in the MEN Consortium of Japan database, and her clinical features with insulinoma have been briefly described previously (2).
Genetic Analysis
The patient's family members received genetic counseling. Informed consent for a genetic analysis was obtained from the patient with parental permissions. The ethics committee of Kanazawa Medical University approved this study. Genomic DNA was extracted from white blood cells obtained from the patient. PCR and direct sequencing were performed using standard methods. Analysis of MEN1 revealed a novel mutation, p.Gly42Val (c.125G>T), in exon 2 (Fig. 2a) . This substitution was not found in the dbSNP database (http://www.ncbi.nlm.nih. gov/snp) or Human Genetic Variation Database (http://www.genome.med.kyoto-u.ac.jp/SnpDB/). p.Gly42 is strictly conserved in various species (Fig. 2b) . In silico analyses using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and SIFT (http://sift.jcvi.org) predicted p.Gly42Val to be likely damaging.
Discussion
We present herein a MEN1 patient with the complete features of the MEN1 triad that sequentially developed in adolescence; the patient carries a newly identified heterozygous missense mutation (p.Gly42Val) in MEN1. A different missense mutation at the same codon, p.Gly42Asp, has been described previously (3) . p.Gly42 is strictly conserved in various species (Fig. 2a) . This amino acid residue is involved in domains that interact with the transcriptional regulatory proteins, such as Smad3 (codons 40 to 278) and nm23H1 (codons 1 to 486) (1) . Taken together with the predictions based on in silico analyses, a missense mutation at codon 42, i.e., p.Gly42Val and p.Gly42Asp, may affect the functional domains of menin by interfering with the binding of proteins. Although the prognosis of this female patient remains unknown, long-term tumor surveillance is required because Japanese female patients with MEN1 have a high incidence of thymic carcinoid tumors with a high mortality rate (4). Thirteen of 16 reported MEN1 patients who developed GEPNETs before the age of 20 yr had insulinoma (2); therefore, MEN1 gene analysis should be offered to pediatric patients who present with insulinoma.
